SAMN03290942
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- E2F_TARGETS+0.400
- G2M_CHECKPOINT+0.400
- TGF_BETA_SIGNALING+0.400
- INTERFERON_ALPHA_RESPONSE+0.300
- MITOTIC_SPINDLE+0.300
- PROTEIN_SECRETION+0.300
- TNFA_SIGNALING_VIA_NFKB+0.300
- ANDROGEN_RESPONSE+0.200
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.400
- ALLOGRAFT_REJECTION-0.200
- BILE_ACID_METABOLISM-0.200
- ESTROGEN_RESPONSE_EARLY-0.200
- HEME_METABOLISM-0.200
- KRAS_SIGNALING_DN-0.200
- MYC_TARGETS_V1-0.200
- MYC_TARGETS_V2-0.200
- PANCREAS_BETA_CELLS-0.200
- ADIPOGENESIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SAMN03290934 | — | — | 0.854 |
| 2 | SAMN03290946 | — | — | 0.834 |
| 3 | TCGA-44-7662-01A-11R-2066-07 | — | cohortA1 | 0.814 |
| 4 | TCGA-A8-A07I-01A-11R-A00Z-07 | — | C | 0.805 |
| 5 | 198b23eb-5efa-4c7e-84f6-96976474de0b | — | — | 0.800 |
| 6 | TCGA-AR-A250-01A-31R-A169-07 | — | C | 0.793 |
| 7 | f5e6497a-ed39-408d-9034-a965baaafbf7 | — | — | 0.792 |
| 8 | TCGA-FD-A62S-01A-11R-A30C-07 | — | — | 0.792 |
| 9 | 6a43f966-cb2b-47ee-b0f4-c269707daa88 | — | — | 0.779 |
| 10 | TCGA-HD-7753-01A-11R-2081-07 | — | — | 0.767 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.500 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |